Comments on "Importance of Normalization of CA19-9 Levels After Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer''

被引：0
|
作者：
Xu, Hua-Xiang [1 ,2 ,3 ,4 ]
Li, Shuo [1 ,2 ,3 ]
Xu, Shuai-Shuai [1 ,2 ,3 ,4 ]
Liu, Liang [1 ,2 ,3 ,4 ]
Yu, Xian-Jun [1 ,2 ,3 ,4 ]
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Dept Pancreat Surg, Shanghai, Peoples R China
[2] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China
[3] Shanghai Pancreat Canc Inst, Shanghai, Peoples R China
[4] Fudan Univ, Pancreat Canc Inst, Shanghai, Peoples R China
来源：
ANNALS OF SURGERY | 2021年 / 274卷 / 06期
关键词：
RESECTION;
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
引用
收藏
页码：E800 / E801
页数：2
相关论文
共 38 条
  • [31] A preoperative serum signature of CEA+/CA125+/CA19-9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer
    Liu, Liang
    Xu, Huaxiang
    Wang, Wenquan
    Wu, Chuntao
    Chen, Yong
    Yang, Jingxuan
    Cen, Putao
    Xu, Jin
    Liu, Chen
    Long, Jiang
    Guha, Sushovan
    Fu, Deliang
    Ni, Quanxing
    Jatoi, Aminah
    Chari, Suresh
    McCleary-Wheeler, Angela L.
    Fernandez-Zapico, Martin E.
    Li, Min
    Yu, Xianjun
    INTERNATIONAL JOURNAL OF CANCER, 2015, 136 (09) : 2216 - 2227
  • [32] Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study
    Dong, Qian
    Yang, Xiang-hong
    Zhang, Yao
    Jing, Wei
    Zheng, Li-qiang
    Liu, Yun-peng
    Qu, Xiu-juan
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2014, 12
  • [33] Screening for a 177Lu-labeled CA19-9 monoclonal antibody via PET imaging for colorectal cancer therapy
    Wang, Jing
    Zhuo, Liangang
    Zhao, Peng
    Liao, Wei
    Wei, Hongyuan
    Yang, Yuchuan
    Peng, Shuming
    Yang, Xia
    CHINESE CHEMICAL LETTERS, 2022, 33 (07) : 3502 - 3506
  • [34] Roles of metabolic tumor volume and total lesion glycolysis on 18F-FDG PET/CT, CA19-9 levels, and complete blood parameters in predicting survival in patients with unresectable or metastatic pancreatic cancer
    Erdur, Erkan
    Guzel, Yunus
    Yildirim, Ozgen Ahmet
    Poyraz, Kerem
    Yildirim, Mehmet Serdar
    Kaplan, Ilsan
    ANNALI ITALIANI DI CHIRURGIA, 2022, 93 (01) : 48 - 58
  • [35] Adjusting CA19-9 values with clinical stage and bilirubin to better predict survival of resectable pancreatic cancer patients: 5-year-follow-up of a single center
    Wu, Zuowei
    Zhao, Pengcheng
    Wang, Zihe
    Huang, Xing
    Wu, Chao
    Li, Mao
    Wang, Li
    Tian, Bole
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [36] Combination of carbohydrate antigen 19-9 level and tumor size after neoadjuvant chemoradiation therapy may predict early recurrence of resectable pancreatic ductal adenocarcinoma
    Terai, Taichi
    Nagai, Minako
    Nakamura, Kota
    Kohara, Yuichiro
    Yasuda, Satoshi
    Matsuo, Yasuko
    Doi, Shunsuke
    Sakata, Takeshi
    Sho, Masayuki
    PANCREATOLOGY, 2023, 23 (08) : 970 - 977
  • [37] The Relationships Between Perioperative CEA, CA 19-9, and CA 72-4 and Recurrence in Gastric Cancer Patients After Curative Radical Gastrectomy
    Kim, Dae Hoon
    Oh, Seung Jong
    Oh, Cheong Ah
    Choi, Min Gew
    Noh, Jae Hyung
    Sohn, Tae Sung
    Bae, Jae Moon
    Kim, Sung
    JOURNAL OF SURGICAL ONCOLOGY, 2011, 104 (06) : 585 - 591
  • [38] Metastatic Recurrence in a Pancreatic Cancer Patient Derived Orthotopic Xenograft (PDOX) Nude Mouse Model Is Inhibited by Neoadjuvant Chemotherapy in Combination with Fluorescence-Guided Surgery with an Anti-CA 19-9-Conjugated Fluorophore
    Hiroshima, Yukihiko
    Maawy, Ali
    Zhang, Yong
    Murakami, Takashi
    Momiyama, Masashi
    Mori, Ryutaro
    Matsuyama, Ryusei
    Katz, Matthew H. G.
    Fleming, Jason B.
    Chishima, Takashi
    Tanaka, Kuniya
    Ichikawa, Yasushi
    Endo, Itaru
    Hoffman, Robert M.
    Bouvet, Michael
    PLOS ONE, 2014, 9 (12):
1234